Navigation Links
Amira Pharmaceuticals to Present Preclinical Data on AM152 , an LPA1 Receptor Antagonist, at the Annual Meeting of the American Thoracic Society
Date:5/11/2011

SAN DIEGO, May 11, 2011 /PRNewswire/ -- Amira Pharmaceuticals, Inc. announced today that it will present preclinical data on AM152, an LPA1 receptor antagonist, during the Annual Meeting of the American Thoracic Society (ATS) in Denver, Colorado.  The poster, titled "The LPA1 Antagonist, AM152, Is Efficacious in Mouse Models of Fibrosis," will be presented on Monday, May 16, from 8:15 to 10:45 a.m. MDT.

The LPA1 receptor is part of the lysophosphatidic acid signaling pathway.  Under pathological conditions, LPA1 is associated with a breakdown of the endothelial barrier and the stimulation of fibroblast recruitment, proliferation and transformation, resulting in excessive deposition of extracellular matrix proteins.  Studies have shown that the LPA1 receptor may play a role in several fibrotic diseases, including Idiopathic Pulmonary Fibrosis (IPF).

"Our preclinical data demonstrate that AM152 reduces pro-fibrotic activity by fibroblasts in vitro and tissue fibrosis in numerous in vivo models," said Gretchen Bain, Ph.D., Executive Director of Biology.  "AM152 reduces fibrosis in multiple tissue types thus providing a strong rationale for clinical exploration in patients suffering from a variety of fibrotic diseases."

Bob Baltera, Chief Executive Officer, added, "Our lead LPA1 program, AM152, is one of the cornerstones for Amira's future.  As previously disclosed, we look forward to initiating Phase 2a clinical studies in patients suffering from fibrotic disease in order to explore the therapeutic benefit of this compound."

About Amira

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory and fibrotic diseases.  Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an enviro
'/>"/>

SOURCE Amira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Amira Pharmaceuticals Announces Completion of Phase 1 Clinical Study for AM152, A Novel LPA1 Receptor Antagonist
2. Amira Pharmaceuticals Receives Orphan Drug Status for a Novel LPA1 Antagonist, AM152, for the Treatment of Idiopathic Pulmonary Fibrosis
3. Amira Pharmaceuticals Announces the Nomination of an Orally Available Pre-Clinical Candidate in a New LPA-Related Program, an Autotaxin Inhibitor
4. Amira Pharmaceuticals Announces Initiation of Phase I Clinical Trial for AM152, A Novel LPA1 Antagonist
5. Amira Pharmaceuticals Announces IND Submission for Novel LPA1 Antagonist, AM152, for Potential Use in Fibrotic Diseases
6. Amira Pharmaceuticals Named One of Most Promising Biotech Companies by FierceBiotechs Annual Fierce 15
7. Visage Imaging Releases Amira 5.3
8. Amira Announces AM103 and AM803 Patent Grant in the United Kingdom
9. Amira Announces Second DP2 Antagonist Patent Grant in the United Kingdom
10. Anti-Fibrotic Data from Amira Pharmaceuticals LPA1 Receptor Antagonist Program Published in the British Journal of Pharmacology
11. Amira Pharmaceuticals Announces Efficacy of LPA1 Antagonist in a Preclinical Model of Scleroderma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... SINGAPORE , March 2, 2015 Mount ... center in Singapore to treat ... radiosurgery from Varian Medical Systems (NYSE: VAR ... introduced the new system, which enables advanced forms of ... shaped high-energy radiation beams to attack a tumor from ...
(Date:3/2/2015)... 2015 Valencia Technologies Corporation (" Valencia ... its radically small device for the treatment of high ... this randomized, double-blinded, controlled trial are compelling and provide ... it will succeed in a large U.S. trial for ... Valencia has successfully raised more ...
(Date:3/2/2015)... , March 2, 2015  CytomX, a ... of cancer, today announced the creation of scientific ... and clinicians in the fields of cancer immunotherapy ... new advisory boards will provide guidance to CytomX ... of precision immunotherapies and Probody drug conjugates. The ...
Breaking Medicine Technology:Mount Elizabeth Novena Hospital to Deliver First TrueBeam STx Radiosurgery Treatments in Singapore 2Mount Elizabeth Novena Hospital to Deliver First TrueBeam STx Radiosurgery Treatments in Singapore 3Valencia Technologies Implants its 48th Patient, Continues Equity Crowdfunding 2CytomX Expands Scientific and Clinical Advisory Boards with Leading Experts in Cancer Immunotherapy and Antibody Drug Conjugates 2CytomX Expands Scientific and Clinical Advisory Boards with Leading Experts in Cancer Immunotherapy and Antibody Drug Conjugates 3
... Following recent FDA approvals for prostate cancer treatment ... that the lives of men with advanced prostate cancer ... medication from Johnson & Johnson. The drug, which could reach ... news with the potential to change clinical practice by ...
... SPRING, Md., Oct. 13 The Food and Drug Administration ... a rare type of thigh bone fracture in people ... (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) (Logo: ... warning because the rare type of fracture has been ...
Cached Medicine Technology:Robotic Prostatectomy Expert Dr. David Samadi, MD Discusses Prostate Cancer Treatment Drug Abiraterone 2
(Date:3/2/2015)... March 02, 2015 Burns Engineering's ... calibration for Secondary Standard Platinum Resistance Thermometers (SSPRTs) ... business days or less . . . guaranteed. ... ® Accredited (Lab Code 200706-0), ISO 9001 and ... Temperature range is -196°C to 500°C, both ITS-90 ...
(Date:3/2/2015)... 2015 The minimally invasive surgical ... CAGR of 6.1% to reach $14,133.0 million by ... Factors such as advantages of minimally invasive surgeries ... to minimally invasive surgeries and increasing number of ... the global minimally invasive surgical instruments market. , ...
(Date:3/2/2015)... Four Seasons Resort Maui at Wailea, the ... this year, having officially opened its doors on March 2, ... honoring over 70 employees who started on Day 1 and ... approximately 400 original employees. The celebration will be a ... , This Four Seasons flagship resort, the first resort ...
(Date:3/2/2015)... March 02, 2015 The Alliance for ... safety expert Mark Chubb to serve as chief safety ... operations and training in Bangladesh and guide remediation efforts ... , “Mark will ensure that the Alliance continues to ... programs for Bangladesh garment workers,” said Alliance Independent Chair ...
(Date:3/2/2015)... Secura Consultants announced today the ... Protective Insurance Group of Birmingham, AL (First Protective). ... affiliated advisors to access the enhanced disability income ... delivers. , Secura Consultants, based in ... design and implementation of insured income protection programs. ...
Breaking Medicine News(10 mins):Health News:Burns Engineering Announces Quick-Turn Temperature Calibrations 2Health News:Minimally Invasive Surgical Instrument Market - Global Forecast to 2019 - New Report by MarketsandMarkets 2Health News:Celebrating Four Seasons Resort Maui’s 25th Anniversary 2Health News:Alliance for Bangladesh Worker Safety Names New Chief Safety Officer 2Health News:Secura Consultants and First Protective Insurance Group Announce Strategic Relationship 2
... leading journal Value in Health , the study ... cost effectiveness and fairness. The researchers concluded that ... have real benefits in terms of both economic efficiency ... other fatal diseases with similar age distributions. ...
... April 1, 2010 -- A resource for medical educators ... tools and resources, and advancing their careers in medical ... Physicians (ACP). "The Teaching Medicine series is the ... series editor, "This series summarizes the important literature of ...
... Care is undertaking an electronic medical record integration project ... is a multi-year, multi-entity corporate initiative to implement common ... in processes and workflows across the system. Currently in ... next four years, the way UMass Memorial collects, views, ...
... students, grades, study found , THURSDAY, April 1 (HealthDay News) ... more likely? , Perhaps, according to a study that found ... college students, grades. , Test-takers who saw the letter at the ... with a grade, scored significantly worse than those who saw an ...
... promise for women at increased risk , THURSDAY, April 1 (HealthDay ... greatly boosts the risk that a woman will develop breast cancer. ... risk of cancer in mice with that gene by deactivating another ... an 85 percent greater lifetime risk for developing breast cancer than ...
... hyperthyroidism should have it treated to reduce their ... -- Young adults who have an overactive thyroid face ... the condition, Taiwanese researchers report. , "This is a ... treatment to prevent these complications," Dr. Majaz Moonis, ...
Cached Medicine News:Health News:UMass Memorial health care develops fully integrated EMR 2Health News:Seeing Letter 'F' May Lower Test Scores 2Health News:Overactive Thyroid Linked to Stroke in Young Adults 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: